Gemini Therapeutics (NASDAQ:GMTX) Shares Down 2.6% – What’s Next?

Gemini Therapeutics, Inc. (NASDAQ:GMTX)’s share price dropped 2.6% on Thursday . The stock traded as low as $79.0933 and last traded at $80.01. Approximately 413,096 shares were traded during mid-day trading, an increase of 118% from the average daily volume of 189,291 shares. The stock had previously closed at $82.14.

Gemini Therapeutics Stock Performance

The stock’s fifty day simple moving average is $83.78 and its 200-day simple moving average is $73.67. The stock has a market cap of $3.47 billion, a P/E ratio of -80.01 and a beta of -0.12.

Gemini Therapeutics Company Profile

Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.